Table 2. Pharmacological therapies for COPD.
S. No |
Class of medication |
Action |
Generic name of the drug |
Ref. |
1. |
Bronchodilators (Beta2-Agonist) |
Increases FEV1 by relaxing the airway smooth muscle. Stimulates beta2-adrenergic receptors to increase cyclic AMP and works against bronchoconstriction. |
Formoterol, Salmeterol |
[94] |
2. |
Antimuscarinics |
Blocks the effect of acetylcholine on M3 muscarinic receptor against bronchoconstriction of airway smooth muscles |
Tiotropium, Umeclidinium |
[95] |
3. |
Methylxanthins |
Act as non-selective phosphodiesterase inhibitor |
Theophyllin, Aminophylline |
[96] |
4. |
Inhaled corticosteroids (ICS) |
Used to control exacerbations in COPD patients |
Fluticasone, Budisonide, Prednisolone |
[97] |
5. |
Combination bronchodilator therapy |
Shortacting Beta2-Agonist / short-acting muscarinic antagonists (SABA/SAMA) |
Formoterol and tiotropium |
[98] |
Long acting Beta2-Agonist / long-acting muscarinic antagonists (LABA/LAMA) |
Formoterol/aclidinium, Formoterol/glycopyrronium |
|||
LABA/ICS |
Salmeterol/fluticasone, Formoterol/budesonide |
|||
6. |
Triple therapy |
LABA/LAMA/ICS |
Fluticasone/umeclidinium/vilanterol |
[99] |
7. |
Phosphodiesterase-4 (PDE4) inhibitor |
Reduces inflammation by inhibiting the breakdown of intercellular cyclic AMP |
Roflumilast |
[100] |
8. |
Antibiotics, mucolytic and antioxidant agents |
Targets anti-inflammatory pathways |
Azithromycin, Simvastatin, Erdosteine, Carbocysteine, N-acetylcysteine |
[101] |